Solid Dosage Products: Tracking the Market

What are key moves and trends by CDMOs/CMOs and suppliers in the oral solid-dosage market? A look at key market and technology developments.

Solid growth
The global oral solid dosage (OSD) contract manufacturing market is expected to reach $54.7 billion by 2030 and expand at a compound annual growth rate (CAGR) of 5.97% from 2024 to 2030, according to a recent analysis by Grand View Research. Increasing complexity of new drug molecules, R&D investments by large CMOs & CDMOs and rising demand for novel therapies are key factors driving market growth.

The tablets segment dominated the market with a revenue share of 32.7% in 2023. Tablets are the most common and preferred OSD form due to their cost-effectiveness, high compactness, easy manufacturing, and convenience of self-administration. Increased demand for bilayer tablets and investments by firms to expand formulation and controlled-release tablet manufacturing are predicted to drive market growth

The controlled-release segment accounted for the largest share with 52.2% in 2023. This growth is attributed to advancements in oral controlled-release delivery systems, including dome tablets, dual drug tablets, intestinal patches, polymer nanosystems, and bioinspired delivery methods, such as exosomes for precise drug delivery. Thus, high demand for controlled-release dosage forms is anticipated to boost segmental revenue growth in the near future

Based on end-use, the large-size companies segment accounted for the largest share in 2023 with a 54.8% share, according to Grand View Research The solid dose manufacturing market is increasingly defined by collaboration, flexibility, and high adaptability. More pharma developers design drugs from the start, intending to outsource them to large CMOs, thereby accelerating market growth. Furthermore, CMOs specializing in oral solid dosage can provide several benefits to large pharmaceutical companies, leading to their increased adoption

Asia-Pacific led the global market in 2023 on a geographic growth basis and is projected to see the fastest CAGR of 6.3% during the forecast years, led by growth in China and India. Expanding manufacturing capabilities among Asian countries such as Singapore, India, and South Korea will also contribute to growth in the region.

Recent Feature Articles

CDMOs: Biomanufacturing Expansion Updates

By
Expansions in biomanufacturing (biologic drug substances) continues to be an active area of investment by CDMOs/CMOs. Which companies are expanding? DCAT Value Chain Insights rounds up the latest developments.

Tariffs, Strategies & Biotech: Where Do Things Stand?

By
Biotech industry groups, Biotechnology Innovation Organization (US) and EuropaBio (Europe), weigh in on evolving US trade policy and how to strengthen the life-sciences industry’s competitiveness.

Tariffs & Pharmaceuticals: US Government Takes the Next Step

By
The US Secretary of Commerce has initiated an investigation to determine the effects on US national security of imports of pharmaceuticals, including finished drug products, active pharmaceutical ingredients (APIs), and key starting materials, potentially paving the way for pharmaceutical industry-specific tariffs.

Small-Molecules’ Gain: Trump Signs Executive Order on Drug Pricing

By
President Donald Trump has signed an Executive Order on drug pricing, which calls for eliminating the so-called “pill penalty” under the Medicare Prescription Drug Negotiation Program to equalize the post-approval time frame for drugs subject to negotiation for small-molecule drugs and biologics.